A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.

Peter Bach, Jonas Boström, Kay Brickmann, J J J van Giezen, Ragnar Hovland, Annika U Petersson, Asim Ray, Fredrik Zetterberg

Department of Medicinal Chemistry, AstraZeneca R&D, Pepparedsleden 1, S-43183 Mölndal, Sweden. Peter.Bach@astrazeneca.com

Bioorganic & medicinal chemistry letters 2011 May 15

filter terms:

A novel series of P2Y(12) antagonists for development of drugs within the antiplatelet area is presented. The synthesis of the piperazinyl-pyridine urea derivatives and their structure-activity relationships (SAR) are described. Several compounds showed P2Y(12) antagonistic activities in the sub-micromolar range. Copyright © 2011 Elsevier Ltd. All rights reserved.

Citation

Peter Bach, Jonas Boström, Kay Brickmann, J J J van Giezen, Ragnar Hovland, Annika U Petersson, Asim Ray, Fredrik Zetterberg. A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor. Bioorganic & medicinal chemistry letters. 2011 May 15;21(10):2877-81